Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabineは一種のDNA methylationの有効な阻害剤で、骨髄異形成症候群(MDS)を治療することに使用されます。
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NYnVbVJkTnWwY4Tpc44hSXO|YYm= Mn;aNE42yqEQvF2= MXKyOEBp M2PtcpdifGW{ NYPTSoFNdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? M2PmR|I2OTJ|MEiy
Eca109 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXGSYMxNjVxMj61M|Uh|ryP NYfBZm1UOjRxNEivO|IhcA>? M1L4e5difGW{ NV3oO3R7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1LHXlI2OTJ|MEiy
Eca109 NXzGWWtyTnWwY4Tpc44hSXO|YYm= NFvtO5MxNjYEoN88US=> M4rGPFYwOTJxMkSgbC=> Mm\we4F1\XJ? M1uxbYlvcGmkaYTzJINmdGxibXnndoF1cW:wwrC= M3vWc|I2OTJ|MEiy
Eca109 MlLuSpVv[3Srb36gRZN{[Xl? NXT6fY5IOC53wrFOwG0> MX:yOEBp NHP1[Wd4[XSnch?= NX3jV5g3cW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MoD1NlUyOjNyOEK=
Eca109 NWS3bWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDRNE42yqEQvF2= NIi0PWQzPCCq MXj3ZZRmeg>? NF3NOGVqdmS3Y3XzJGczN01iYYLy[ZN1KGmwIITo[UBk\WyuIHP5Z4xm M364clI2OTJ|MEiy
Eca109 M2jBZ2Z2dmO2aX;uJGF{e2G7 NVrtRW9bOC53L{Gg{txO NWexXFBIOjRiaB?= NW\v[2Vnf2G2ZYK= MWLk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz NITEdWEzPTF{M{C4Ni=>
SW1116  NHuy[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[yU|AvPS9zL{KvOUDPxE1? MlrmOFghcA>? NF3oO|NFVVOR M1LtOoVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NWrSZWFuOjR6N{SyPFY>
LOVO M2Dme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITSTnQxNjVxMT:yM|Uh|ryP NUnC[3p[PDhiaB?= M3ntTWROW09? NGnpVVBmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NVraR2k5OjR6N{SyPFY>
SW1116  M3i2UmZ2dmO2aX;uJGF{e2G7 NIDQe2gyOCEQvF2= MWq0PEBp MWHEUXNQ NVL4eWZpcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NV;GSY9ZOjR6N{SyPFY>
LOVO NGfJflBHfW6ldHnvckBCe3OjeR?= MXuxNEDPxE1? NXnMVIU2PDhiaB?= NVT1SlhITE2VTx?= NGTwd|JqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M4K0W|I1QDd2Mki2
SW1116  M12zR2Fxd3C2b4Ppd{BCe3OjeR?= MoryNVAh|ryP NFjyS5M1QCCq M{fqUGROW09? Mmjo[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NFLqd3MzPDh5NEK4Oi=>
LOVO NH3DOoxCeG:ydH;zbZMhSXO|YYm= NEPCdI4yOCEQvF2= M2fwOVQ5KGh? NF3YT5BFVVOR Ml7z[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz M3TObFI1QDd2Mki2
RPMI-8226 MVHBdI9xfG:|aYOgRZN{[Xl? MkjwNU8zKM7:TR?= NX2x[HRyPDhxN{KvPVYhcA>? MlvaSG1UVw>? M3j1eIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHTUVYEzPDh|M{GwPC=>
OPM-2  NITRdGVCeG:ydH;zbZMhSXO|YYm= M1\0OVEwOiEQvF2= MXm3Nk86Pi9zMkCgbC=> M2TLW2ROW09? NEjtbmpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkHLNlQ5OzNzMEi=
JJN3  Ml[zRZBweHSxc3nzJGF{e2G7 M4TFdFAvPS9zIN88US=> MWOyOE81QCCq NXzkcIlqTE2VTx?= MkLhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlfNNlQ5OzNzMEi=
NCI-H929  M1zqb2Fxd3C2b4Ppd{BCe3OjeR?= MmroNU8zKM7:TR?= NV7pN5BUPzJxOU[vNVIxKGh? MUHEUXNQ NEX4TYlqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHf1XJUzPDh|M{GwPC=>
RPMI-8226 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXyxM|Ih|ryP NIm2S4YzPC92OD:3NkBp MVXEUXNQ MVLh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MWCyOFg{OzFyOB?=
OPM-2  NVHSfGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wSVUyNzJizszN NILFNW4zPC92OD:3NkBp MmntSG1UVw>? NHfPXpZi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MV6yOFg{OzFyOB?=
JJN3  M{PPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i2RVAvPS9zIN88US=> MmT0NlQwPDhxN{KgbC=> MYrEUXNQ MX3h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NIn0RXUzPDh|M{GwPC=>
NCI-H929  NIXYUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG5S5IyNzJizszN NF\mSmUzPC92OD:3NkBp MnHuSG1UVw>? NXzRTZZJ[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NHPPTVEzPDh|M{GwPC=>
HeLa NVfIfpF6U2mwYYPlJGF{e2G7 NWHxWYtCU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? MljjNlQ4QDByOUi=
HeLa MU\LbY5ie2ViQYPzZZk> NH30R41McT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> MmLBNlQ4QDByOUi=
HeLa Mn61T4lv[XOnIFHzd4F6 NVHmblJDU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? MWSyOFc5ODB7OB?=
HeLa NE\wPGtMcW6jc3WgRZN{[Xl? NIr2eIlMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{ MXKyOFc5ODB7OB?=
NB4 MX7GeY5kfGmxbjDBd5NigQ>? MnPYNk42NzVxNz61M|ExKM7:TR?= MX2yOEBp M1;nWmROW09? MYfpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NGHITnMzPDR6NEi3NC=>
CD4+ CD25− T  NGrwRlNHfW6ldHnvckBCe3OjeR?= NEW2ZmYyNzVizszN NXLRbnlNemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w NIrzfHkzPDR5NkO2NC=>
BV-173 M{\DRmFxd3C2b4Ppd{BCe3OjeR?= NHTJdZkxNjJ3L{CuOU8xNjd3L{Gg{txO MVO0PE84Oi97NjDo M{fD[eKhWEKV MXPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MU[yOFQzOzZzMx?=
ML-1 NHTWPXpCeG:ydH;zbZMhSXO|YYm= NYPpSmtJOC5{NT:wMlUwOC55NT:xJO69VQ>? M3iwXVQ5Nzd{L{m2JIg> M3u4eOKhWEKV NXGxXXJZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NF7EOVQzPDR{M{[xNy=>
HL-60 Ml[zRZBweHSxc3nzJGF{e2G7 NY\5dlRUOC5{NT:wMlUwOC55NT:xJO69VQ>? NFHBPVc1QC95Mj:5OkBp MXRCpHBDWw>? M4LpTIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHHlcFgzPDR{M{[xNy=>
KG-1a NISxVHBCeG:ydH;zbZMhSXO|YYm= M{SxXVAvOjVxMD61M|AvPzVxMTFOwG0> NUTPW3pKPDhxN{KvPVYhcA>? MURCpHBDWw>? NFfBWJhqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MYKyOFQzOzZzMx?=
BV-173 MULGeY5kfGmxbjDBd5NigQ>? M13obFI2OC93MEDuUS=> Mn:0OFghcA>? Mn\kxsBRSlN? MoLjbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M1TGWFI1PDJ|NkGz
CEM M33ZOWZ2dmO2aX;uJGF{e2G7 MVSyOVAwPTBybl2= NWXaUndHPDhiaB?= NIL5TVPDqFCEUx?= MlKybY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NELKeHEzPDR{M{[xNy=>
HL-60 NVT3Xlg1TnWwY4Tpc44hSXO|YYm= MYSyOVAwPTBybl2= MmX5OFghcA>? NEW3Wm/DqFCEUx?= NHr0RXBqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NX\1d48xOjR2MkO2NVM>
ML-1 MULGeY5kfGmxbjDBd5NigQ>? MXqyOVAwPTBybl2= M2\SRVQ5KGh? MkTFxsBRSlN? Mn\obY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MoriNlQ1OjN4MUO=
DLD-1 MnvRSpVv[3Srb36gRZN{[Xl? NHPqZXEzPTBxNUCwcm0> NH3TZ4U1QCCq NULzdJZ3yqCSQmO= Mk\S[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? M4DZPFI1PDJ|NkGz
HCT-116 MULGeY5kfGmxbjDBd5NigQ>? MXiyOVAwPTBybl2= M1v0OVQ5KGh? NIDqNXbDqFCEUx?= M{LRWoRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NXz4e3lOOjR2MkO2NVM>
U937-A/E-9/14/18  NYLzNHBbSXCxcITvd4l{KEG|c3H5 NFnlZ4UxNjBzL{CuNU8yNzFyIN88US=> NEDzcW01QCCq MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mk\MNlQ{ODB2NU[=
HT29 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLRS3NxPzJiaB?= MmTvTWM2OD1zNECwxtEyPzlizszN M2\sPVI1OTd{ME[x
SW48 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;wO|IhcA>? MY\JR|UxRTF3LkNCtVYvOiEQvF2= NY\5Z3pHOjRzN{KwOlE>
HCT116 NV;zfnpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX63NkBp MkfxTWM2OD1zLkhCtVAvPCEQvF2= MVuyOFE4OjB4MR?=
HepG2 NUm3e5lvTnWwY4Tpc44hSXO|YYm= M3u5UVAvPS9zIN88US=> MljRNlQhcA>? MYLEUXNQ NUTyV49EfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NYT5co5nOjRzNE[4O|Q>
LS174T MVLGeY5kfGmxbjDBd5NigQ>? NHPwUWwxNjVxMTFOwG0> NHvTSIQzPCCq MUTEUXNQ MX7s[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= M1yy[lI1OTR4OEe0
HepG2 NIfYNHlCeG:ydH;zbZMhSXO|YYm= NHnZVnQyNzFyL{GwNEDPxE1? NEXuO|Y4KGR? MojPSG1UVw>? NIjje4lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mkm0NlQyPDZ6N{S=
LS174T NW\ReZU4SXCxcITvd4l{KEG|c3H5 NX\HZ2RyOS9zMD:xNFAh|ryP M2HqWVch\A>? MV\EUXNQ M3fzUolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXGyOFE1Pjh5NB?=
QBC-939 NXmxTpRZSXCxcITvd4l{KEG|c3H5 NXrlfVZQOS9zMD:xNFAh|ryP NEXpV5A4KGR? MVLEUXNQ NFL1[VRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkXwNlQyPDZ6N{S=
U251 NHz1bm1CeG:ydH;zbZMhSXO|YYm= MkTFNU8yOC9zMECg{txO MoT4O{Bl NYDUU4lpTE2VTx?= NHXMN4NqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWmyOFE1Pjh5NB?=
HL-60 M1e4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV:xJO69VQ>? MVi0PEBp NGPqUo9qdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= M3TQfVI1ODByM{K0
MDA‑MB‑453 NU[3[XkxTnWwY4Tpc44hSXO|YYm= MnHvNE4zNzFizszN NVjOcWMzPzJiaB?= M1f3[4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M2X3eVI{QDR2MkK4
HCC1569 M3nPSGZ2dmO2aX;uJGF{e2G7 NGfvTHIxNjJxMTFOwG0> NHnVNW84OiCq NX[2PVVp[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NYX0[VE4OjN6NESyNlg>
BT‑474 MUnGeY5kfGmxbjDBd5NigQ>? MVOwMlIwOSEQvF2= NFqxeXQ4OiCq MUDjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M2nIZ|I{QDR2MkK4
AGS M1rlUWFxd3C2b4Ppd{BCe3OjeR?= NYrjN217PS9zMD:yNE82OCEQvF2= NWTudGttPDkEoHlCpC=> NInydmtFVVOR M1XtSIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M1joUVI{PTh{N{i0
A549 NELxXWdCeG:ydH;zbZMhSXO|YYm= NWHZdnpTPS9zMD:yNE82OCEQvF2= NG\n[WI1QMLiaNMg NWDSTIZTTE2VTx?= NIHZVYlqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NYPEdmF7OjN3OEK3PFQ>
AGS  M4KzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nEUlUwOTBxMkCvOVAh|ryP NYjnco5PPDkEoHlCpC=> NGXyOFBFVVOR MWPpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NVfBUploOjN3OEK3PFQ>
Kasumi-1 NIfUTYdCeG:ydH;zbZMhSXO|YYm= NVzq[o5HOC53IN88US=> MWG0POKhcMLi M{DEWoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MkC4NlM1QTN|NEi=
OCI-AML3 NGjN[mJCeG:ydH;zbZMhSXO|YYm= M3nWOlIvPSEQvF2= NYDyTXViPDkEoHlCpC=> NIS4clZl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NWXHem9SOjN2OUOzOFg>
MV4-11 MWTBdI9xfG:|aYOgRZN{[Xl? NXKyT2s4Oi53IN88US=> MXS0POKhcMLi MWTk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NXH5R3hKOjN2OUOzOFg>
NK  MlrCR5l1d3SxeHn0fUBCe3OjeR?= M{fhSlAvODJvMkCg{txO M3rxflUh\A>? M37hUYRm[3KnYYPld{B1cGViY4n0c4x6fGmlIHHjeIl3cXS7IH;mJG5MKGOnbHzzJIF1KGmwdHXycYVlcWG2ZTDjc45k\W62cnH0bY9veyC{ZYP1cJRqdmdiaX6gZUBWNXOqYYDl[EBld3On4pETdoV{eG:wc3WgZ5VzfmV? MkfNNlM{OjhyOEi=
NK  MkHvRZBweHSxc3nzJGF{e2G7 MVGwMlAzNTJyIN88US=> M4P0bVUh\A>? NHLGeIdl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NEHuWIQzOzN{OEC4PC=>
NK  MV\GeY5kfGmxbjDBd5NigQ>? NIXuSGsxNjBzLUKwJO69VQ>? NEC5OFQ2KGR? MmH4Z4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> M{m4OVI{OzJ6MEi4
MOLT4/DNR MWfGeY5kfGmxbjDBd5NigQ>? MnzpOUDPxE1? MnXnOEBl M4n5NJJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NFv1PJQzOzB4MEW3NC=>
Jurkat/DOX MojhSpVv[3Srb36gRZN{[Xl? NHjHc3g2KM7:TR?= NUfpdnY4PCCm NFT4fnRz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? NYryVpMzOjNyNkC1O|A>
MOLT4/DNR NGXYdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\JfWtjPSEQvF2= NGLZVHM1KGR? M2m5b5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MWGyN|A3ODV5MB?=
Jurkat/DOX M1HCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r1Z|Uh|ryP NV\6cZh3PCCm M1\ZWJJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MoD6NlMxPjB3N{C=
ccRCC  M3K5SWFxd3C2b4Ppd{BCe3OjeR?= M{X1SlAvODFvMUFOwG0> MXy3NkBp M3[2bWROW09? MWDoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NFn2PZkzOjh{NkS2Oy=>
TNBC  MoPKRZBweHSxc3nzJGF{e2G7 NIjiemgxNjBzLUGw{txO M1nzU|czKGh? NEm2PIdFVVOR Mom0bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MUWyNlgzPjR4Nx?=
A498 NYD3WWZqSXCxcITvd4l{KEG|c3H5 MUmwMlAyNTFyzszN MVe3NkBp MUfEUXNQ NWqxR3F2cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NHOweW0zOjh{NkS2Oy=>
KIJ265T NIfhNFZCeG:ydH;zbZMhSXO|YYm= M3fMd|AvODFvMUFOwG0> NH\Sd3k4OiCq MUPEUXNQ NF62NHdqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M2X4UVIzQDJ4NE[3
MDA-231 MmPoRZBweHSxc3nzJGF{e2G7 NIXSc2cxNjBzLUGw{txO MUe3NkBp M{TWSmROW09? MU\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NUWy[FlNOjJ6Mk[0Olc>
BT-20 M2\SOmFxd3C2b4Ppd{BCe3OjeR?= MV:wMlAyNTFyzszN NVzjR3NPPzJiaB?= M{C5SGROW09? MV\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M1jHRlIzQDJ4NE[3
U937 M1vDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq1MVIxKM7:TR?= MYeyOE81QC95MjDo MY\pcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MXeyNlc3PzB{MR?=
HL60 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rPOVUuOjBizszN MVKyOE81QC95MjDo NVHmUo1{cW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NEHMemczOjd4N{CyNS=>
U937 MnvaRZBweHSxc3nzJGF{e2G7 MlXKNVUh|ryP M4rkflI1NzR6L{eyJIg> M37odYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3rpd|IzPzZ5MEKx
HL60 MV3BdI9xfG:|aYOgRZN{[Xl? NUjmbIJIOTVizszN M3rESlI1NzR6L{eyJIg> MUXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYS5bWVSOjJ5NkewNlE>
LS411N  MVXBdI9xfG:|aYOgRZN{[Xl? M3u0TVAvPSEQvF2= NXPyWWNxPzJiaB?= MUPpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? NWDJNotqOjJ2NkG2PVU>
MDA-MB-231 MX;BdI9xfG:|aYOgRZN{[Xl? NH\kN5IyOCEQvF2= MoTwOFghcA>? MmPpdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUfyb5lKOjF6OEe2PVc>
MCF-7  MWXBdI9xfG:|aYOgRZN{[Xl? MXqxNEDPxE1? NX\ETYw3PDhiaB?= MoP6doVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NV\0[2E{OjF6OEe2PVc>
A375 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq1NE42KM7:TR?= MWixM|UwQCCm MV\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MXmyNVc6PjZ{Mh?=
SKMEL1 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fzNlAvPSEQvF2= NXnueWxsOS93L{ig[C=> MYTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MnXQNlE4QTZ4MkK=
SKMEL3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlUh|ryP NIPXcJcyNzVxODDk M1O0VYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NGXTT44zOTd7Nk[yNi=>
SKMEL28 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCwMlUh|ryP NIOyV4kyNzVxODDk MYnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MUeyNVc6PjZ{Mh?=
MeWo M3fS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMlUh|ryP NWj2fYFxOS93L{ig[C=> M1\3eIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MW[yNVc6PjZ{Mh?=
B16 M{fQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTlRZExNjVizszN MnuwNU82NzhiZB?= NGjvWnFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MXmyNVc6PjZ{Mh?=
Ly 1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLmcI15OjRiaB?= NVT1SYVjUUN3ME23MlMh|ryP NV7YNYlGOjF5N{KwOFk>
Ly 7 M13V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSNlQhcA>? M3vkbWlEPTB;MUCuO{DPxE1? M{f4VlIyPzd{MES5
Su-DHL6 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\zTXNwOjRiaB?= MXTJR|Ux97zgMkCg{txO MkLJNlE4PzJyNEm=
Ly 10 M17Rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\uclQzPCCq NFvYXohKSzVy78{eNlAh|ryP NWT1e2M6OjF5N{KwOFk>
RIVA MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M170N|I1KGh? NXPQXY1UUUN3MP-8olIxKM7:TR?= MojkNlE4PzJyNEm=
Su-DHL2 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSyOEBp M37BWGlEPTExvK6yNEDPxE1? MYqyNVc4OjB2OR?=
Ly 1 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrXNpk1QCCq NF:zeXBKSzVyPUCuN|Qh|ryP MofjNlE4PzJyNEm=
Ly 7 MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfsXYxOPDhiaB?= MkPvTWM2OD1yLkCyOUDPxE1? MmrxNlE4PzJyNEm=
Su-DHL6 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojCOFghcA>? MnPETWM2OO,:nkKwJO69VQ>? Mk[3NlE4PzJyNEm=
Ly 10 NUG2SXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzRdXg1QCCq M33aWmlEPTB;MT64JO69VQ>? M3jOVFIyPzd{MES5
RIVA MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33tTVQ5KGh? NFH6[IxKSzVy78{eNlAh|ryP M1zBNVIyPzd{MES5
Su-DHL2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m5SVQ5KGh? MmrWTWM2OD1zNz60JO69VQ>? MkfONlE4PzJyNEm=
Ly 1 NGe4eIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITpOWU4OiCq NF2zNotKSzVyPUCuNFEh|ryP NV7hfHRMOjF5N{KwOFk>
Ly 7 NEDifoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp NX7X[YNNUUN3ME2wMlAyQCEQvF2= NVi0dlFlOjF5N{KwOFk>
Su-DHL6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTUO|IhcA>? NYDiXFh2UUN3ME2xMlYh|ryP MUGyNVc4OjB2OR?=
Ly 10 NEW1UnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHhdJM4OiCq MkD1TWM2OD1zLkKg{txO Mo\QNlE4PzJyNEm=
RIVA NUnjcmFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\FZllLPzJiaB?= NYDpVWV5UUN3MP-8olIxKM7:TR?= NHTzbpczOTd5MkC0PS=>
Su-DHL2 NIr1UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3NkBp MVfJR|UxRTFzLkKg{txO MnnMNlE4PzJyNEm=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

Related Antibodies

DNA Methyltransferase信号経路図

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID